Famitinib trials for HER2-negative Breast Cancer

All Famitinib trials · All HER2-negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Famitinib for HER2-negative Breast Cancer

• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
  NCT06516289 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
  NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SNF Platform Study of HR+/ HER2-advanced Breast Cancer
  NCT05594095 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study Famitinib for HER2-negative Breast Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.